FDA Clears Screening Algorithm to Assess for Interstitial Lung Disease
The AI-powered tool automatically assesses medical data for interstitial lung findings compatible with interstitial lung disease.Â
The AI-powered tool automatically assesses medical data for interstitial lung findings compatible with interstitial lung disease.Â
The AI-powered tool automatically assesses medical data for interstitial lung findings compatible with interstitial lung disease.Â
Read MoreThe device is intended to promote and improve bronchial drainage by using high-frequency oscillatory vibrations and intermittent negative pressure.
Read MoreThe FDA says the approval marks the first systemic therapy for non–small cell lung cancer and pancreatic adenocarcinoma harboring NRG1 gene fusions.
Read MoreAstraZeneca’s Imfinzi (durvalumab) has been approved in the United States for the treatment of adult patients with limited-stage small cell lung cancer.
Read MoreMovano Health has secured US Food and Drug Administration clearance for the pulse oximeter in the EvieMED Ring.
Read MoreThe FDA has granted 510(k) clearance for an over-the-counter fingertip pulse oximeter designed to provide accurate blood oxygen readings across all skin tones.
Read MoreThe cloud-based monitoring solution uses a single-use biosensor to track vital signs like SpO2, ECG, and body temperature across home, remote, and hospital settings.
Read MoreCorVent Medical’s Respond ventilator, offering both invasive and non-invasive capabilities, has received FDA 510(k) clearance.
Read MoreThe FDA has approved Dupixent for adults with inadequately controlled COPD and an eosinophilic phenotype.
Read MoreThe FDA has approved osimertinib for adult patients with stage III NSCLC whose tumors have specific EGFR mutations, following chemoradiation therapy.
Read MoreThe nasal spray flu vaccine is available for self- or caregiver-administration by prescription for individuals aged 2 to 49.
Read MoreThe oral appliance is now approved to treat moderate to severe OSA and reduce snoring in children aged 6 to 17.
Read MoreThe FDA has approved Dupixent as an add-on maintenance treatment for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its original approval for adults in 2019.
Read MoreThe US FDA has granted 510(k) clearance to a contactless, under-the-mattress device designed to aid in the diagnosis of obstructive sleep apnea.
Read MoreThe FDA has granted emergency use authorization for an updated Novavax COVID-19 vaccine targeting current variants.Â
Read MoreThe wearable provides continuous, real-time measurement of blood oxygen saturation and pulse rate.
Read MoreThe FDA has approved and authorized updated Moderna and Pfizer-BioNTech COVID-19 vaccines for the 2024-2025 season, designed to target current variants.
Read MoreThe device is intended to be used as an adjunct to reduce bacteria on certain CPAP masks and hoses after cleaning.
Read MoreThe approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Read MoreThe Masimo W1 medical watch, now FDA-cleared for integration with Masimo SafetyNet, enables continuous remote monitoring of vital signs.
Read MoreThe epinephrine nasal spray provides a needle-free option for rapid emergency treatment of severe allergic reactions.
Read MoreThe FDA has approved the next-generation Inspire V therapy system for the treatment of moderate to severe obstructive sleep apnea.
Read MoreThe new AI-powered diagnostic tool is designed to help clinicians identify lung crackles in patients over 2 years old during virtual visits.
Read MorePalforzia is now approved for treating peanut allergies in children ages 1 to 3, expanding its use beyond the previous age range of 4 to 17.
Read More